Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Attention Deficit Hyperactivity Disorder (ADHD)Deficient Emotional Self-Regulation (DESR)
Interventions
DRUG

ADHD Medication

For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.

DRUG

Omega-3 Fatty Acids

Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01399827 - Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits | Biotech Hunter | Biotech Hunter